Skip Ribbon Commands
Skip to main content

Summary Slides

Sharing knowledge. Sharing Hope.
Skip Navigation LinksHome   |   Reference Center   |   Slides and Reports   |   Summary Slides
  • Print
  • Share

Summary Slides - HCT Trends and Survival Data

Using information from our outcomes database, CIBMTR annually prepares and distributes charts summarizing current uses and outcomes of allogeneic and autologous hematopoietic cell transplantation (HCT) in a set of Summary Slides.

Summary Slides

The Summary Slides are an annual report on data submitted to the CIBMTR by centers worldwide and describes information related to practices and general survival outcomes after hematopoietic cell transplantation. The current edition includes transplants performed prior to 2019.

Summary Slides 2019 (PowerPoint)

(Select "Open in PowerPoint" option to view presentation)

  • Slides 3 to 27 exhibit data on frequency of transplants according to age, donor and transplant type, graft source, disease, conditioning regimen, and causes of death. All frequencies represent first autologous and allogeneic transplants registered with the CIBMTR during the period. Slides 3, 4, 17, 18 and 22 represent estimated frequencies of total number of transplants in the US.

  • Slides 28 to 60 include overall survival outcomes according to disease, disease status, donor type, year of transplant and conditioning regimen intensity. Comparisons across survival curves are univariate and do not adjust for all potentially important factors; consequently, results should be interpreted cautiously. Slides demonstrating survival curves represent data from all countries and are not limited to the US only.

Return to top

To cite Summary Slides

D'Souza, A, Fretham C, Lee SJ, et al. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. Biol Blood Marrow Transplant. 2020 May 11:S1083-8791(20)30225-1, doi: 10.1016/j.bbmt.2020.04.013, PMID 32438042.

Return to top

Request Summary Slides

Slides are also available upon request by contacting

Return to top

Supplemental information on Summary Slides

  • Charts on slides 3, 4, 17, 18 and 22 are estimates based on data reported to CIBMTR, adjusted according to transplant type. These adjustments come from comparisons with other national and international databases.
  • Acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and chronic myelogenous leukemia (CML) are classified as:

    • early phase (first complete remission [CR1] or first chronic phase [CP1]),

    • intermediate phase (second or subsequent CR or CP or accelerated phase [AP]), or

    • advanced phase (primary induction failure, active disease or blastic phase) disease.

  • Myelodysplastic syndrome (MDS) is divided into:

    • early (refractory anemia [RA] or refractory anemia with ringed sideroblasts [RARS], refractory cytopenia with unilineage dysplasia [RCUD], refractory cytopenia with multilineage dysplasia [RCMD], MDS with isolated del(5q)).

    • advanced (refractory anemia with excess blasts [RAEB] or chronic myelomonocytic leukemia [CMML]) disease).

  • Myeloproliferative neoplasms (MPNs) include myelofibrosis, polycythemia vera, essential thrombocythemia, chronic myelomonocytic leukemia, chronic myeloproliferative disease-unclassifiable, chronic neutrophilic leukemia, chronic eosinophilic leukemia and MPN-not otherwise specified.

  • Lymphoma is classified according to sensitivity to prior chemotherapy (chemosensitive or chemoresistant).

  • The classification of conditioning regimen intensities is based on the agents, doses and schedules used. Several classifications are available, and for this report we used a composite classification. Cases defined as reduced-intensity by the transplant center were classified as reported. Cases without such information and with available data on chemotherapy agents, radiation and doses, were classified according to the CIBMTR operational definition of conditioning regimen intensity:

    • Myeloablative conditioning: regimens with total body irradiation doses of ≥500 cGY, single fractionated doses of ≥800 cGY, busulfan doses of >9mg/kg, or melphalan doses of >150 mg/m2 given as single agents or in combination with other drugs.

    • Reduced-intensity conditioning: regimens with lower doses of total body irradiation, fractionated radiation therapy, busulfan, and melphalan than those used to define a myeloablative conditioning regimen (above).

Return to top


View current and planned studies
Last Updated: 7/28/2020 10:31 AM